2015 | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. | Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan | J. Clin. Oncol. | | | |
2015 | Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. | Papadimitrakopoulou, Vassiliki; Patnaik, Amita; Borghaei, Hossein; Stevenson, James; Gandhi, Leena; Gubens, Matthew A.; Yang, James Chih-Hsin; Sequist, Lecia V.; Ge, Joy Yang; Bourque, Jennifer; Bachman, Robert D.; Im, Ellie; Gadgeel, Shirish M. | J. Clin. Oncol. | | | |